Compare KLA Corp. (KLAC) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KLA Corp. vs Spyre Therapeutics Inc. Common Stock — how do they compare? KLA Corp. trades at $175.23 (market cap $240.12B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: KLA Corp. is far larger — about 31.9× Spyre Therapeutics Inc. Common Stock's market cap, and KLA Corp. pays a 0.5% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold KLA Corp. for 60 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| KLAC | SYRE | |
|---|---|---|
Market Cap | $240.12B | $7.52B |
Volume | 10,439,404 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $301.71 | $108.92 |
52-Week Low | $108.70 | $22.18 |
Typical Hold Time | 60 Days | 0 Days |
Enterprise Value | $241.37B | $6.52B |
Dividend Yield | 0.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KLA Corporation (KLAC) trades at $178.81, down 5.95% on the day, amid a broader tech selloff. The stock maintains a bullish technical signal, with strong fundamentals including a 35.57% net income margin and consistent earnings beats. Revenue reached $12.16B in 2025, with a robust backlog of $12.57B driven by AI demand, positioning the company for growth in semiconductor equipment.
The outlook remains positive with a consensus price target of $223.88, implying significant upside. Risks include competitive pressures from Applied Materials and ASML, and sensitivity to semiconductor capex cycles. Analyst sentiment is strongly bullish, with 28 buy ratings, supporting a favorable long-term investment case despite near-term volatility.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
